The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
|
|---|---|
| Published in |
OncoTargets and therapy, November 2019
|
| DOI | 10.2147/ott.s214870 |
| Pubmed ID | |
| Authors |
Sri Harsha Tella, Amit Mahipal, Anuhya Kommalapati, Zhaohui Jin |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 27 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 22% |
| Other | 2 | 7% |
| Student > Doctoral Student | 2 | 7% |
| Student > Master | 2 | 7% |
| Student > Ph. D. Student | 2 | 7% |
| Other | 4 | 15% |
| Unknown | 9 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 30% |
| Biochemistry, Genetics and Molecular Biology | 3 | 11% |
| Nursing and Health Professions | 2 | 7% |
| Unspecified | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 10 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2019.
All research outputs
#16,057,393
of 25,387,668 outputs
Outputs from OncoTargets and therapy
#891
of 3,016 outputs
Outputs of similar age
#215,956
of 378,069 outputs
Outputs of similar age from OncoTargets and therapy
#26
of 148 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,069 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 148 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.